AtomMapper is a computational chemistry and AI-driven drug discovery company that specializes in automated atom-to-atom mapping. The company's platform utilizes advanced machine learning algorithms to track individual atoms through complex chemical reactions, providing unprecedented insights into reaction mechanisms and metabolic pathways. This technology is designed to accelerate the lead optimization phase of drug discovery by improving the accuracy of synthetic route prediction and metabolic stability assessments. By integrating deep medicinal chemistry expertise with cutting-edge computational tools, AtomMapper aims to reduce the time and cost associated with developing small molecule therapeutics. The company operates at the intersection of digital health and biotechnology, offering solutions that bridge the gap between theoretical chemistry and practical drug manufacturing.
CLASSIFICATION
Company Type:Digital Health
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:AI Drug Discovery / Computational Chemistry
SIZE & FINANCIALS
Employees:1-50
Revenue:Under $1M
Founded:2022
Ownership:private
Status:operating
FUNDING
Stage:Seed
Total Raised:Estimated $2M-$5M
Investors:Undisclosed Angel Investors, Academic Venture Funds
PIPELINE
Stage:Discovery
Lead Drug Stage:Platform/Discovery
Modalities:Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Columbia University (Research collaboration), Confidential Mid-sized Biotech (Lead optimization partner)
COMPETITION
Position:Emerging
Competitors:Schrodinger, PostEra, Iktos, Exscientia, Relay Therapeutics
LEADERSHIP
Key Executives:
Arie Zask - Co-Founder & Head of Medicinal Chemistry
Scientific Founders:Arie Zask, Academic researchers from Columbia University
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with AtomMapper. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.